Gapping down
In reaction to disappointing earnings/guidance:
- `RAD -7.9%, FUL -6.5%, CAG -6%, PDCO -5.5%, FIZZ -5.3%, MKC -3.7%, WOR -2.8%, ACN -1.8%, NG -1.6%
M&A news:
- WAGE -1.9% (to be acquired by HealthEquity (HQY) for $51.35/share in cash)
Other news:
- ACRS -35.1% (reports Phase 2 clinical trial of ATI-502 topical in patients with alopecia areata did not meet endpoints)
- ZYXI -16.1% (files for ~16.66 mln share common stock offering by selling shareholders)
- MOTS -12.6% (announces public offering of stock)
- IMGN -7.2% (completes operational review, will prioritize continued development of mirvetuximab and a select portfolio of three earlier-stage product candidates targeting solid tumors and hematological malignancies)
- OSTK -5.6% (pulling back along with bitcoin in extended trade)
- BA -2.8% (confirms FAA update; United (UAL) has extended Boeing (BA) 737 Max cancellations until September 3)
- GMDA -2.7% (prices underwritten public offering of 7 mln ordinary shares at a public offering price of $5.00 per share)
- RMR -2.7% (RMR Group client companies price offering of 7,942,245 common shares at $40.00 per common share)
Analyst comments:
- JWN -3.1% (downgraded to Sell from Neutral at Goldman)
- ROST -2.3% (downgraded to Sell from Neutral at Goldman)
- BC -1.1% (downgraded to Neutral from Buy at Northcoast)
- TRV -1.1% (downgraded to Sell from Hold at Deutsche Bank)